August 15, 2019
Marker Therapeutics today announced the appointment of Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs, effective August 15.
August 8, 2019
Marker Therapeutics today provided a corporate update and reported financial results for the second quarter ended June 30, 2019.
August 6, 2019
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Steve Elms, to its Board of Directors, effective August 6.